GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » PB Ratio

SONN (Sonnet BioTherapeutics Holdings) PB Ratio : 0.98 (As of Mar. 30, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-03-30), Sonnet BioTherapeutics Holdings's share price is $1.31. Sonnet BioTherapeutics Holdings's Book Value per Share for the quarter that ended in Dec. 2024 was $1.34. Hence, Sonnet BioTherapeutics Holdings's PB Ratio of today is 0.98.

Good Sign:

Sonnet BioTherapeutics Holdings Inc stock PB Ratio (=0.98) is close to 1-year low of 0.96.

The historical rank and industry rank for Sonnet BioTherapeutics Holdings's PB Ratio or its related term are showing as below:

SONN' s PB Ratio Range Over the Past 10 Years
Min: 0.82   Med: 1.76   Max: 24.37
Current: 0.98

During the past 6 years, Sonnet BioTherapeutics Holdings's highest PB Ratio was 24.37. The lowest was 0.82. And the median was 1.76.

SONN's PB Ratio is ranked better than
78.03% of 1279 companies
in the Biotechnology industry
Industry Median: 2.37 vs SONN: 0.98

During the past 12 months, Sonnet BioTherapeutics Holdings's average Book Value Per Share Growth Rate was -79.90% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Sonnet BioTherapeutics Holdings was 61.80% per year. The lowest was 61.80% per year. And the median was 61.80% per year.

Back to Basics: PB Ratio


Sonnet BioTherapeutics Holdings PB Ratio Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings PB Ratio Chart

Sonnet BioTherapeutics Holdings Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
PB Ratio
Get a 7-Day Free Trial 12.58 1.61 - - -

Sonnet BioTherapeutics Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.08 1.90 1.87 - 1.09

Competitive Comparison of Sonnet BioTherapeutics Holdings's PB Ratio

For the Biotechnology subindustry, Sonnet BioTherapeutics Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonnet BioTherapeutics Holdings's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sonnet BioTherapeutics Holdings's PB Ratio distribution charts can be found below:

* The bar in red indicates where Sonnet BioTherapeutics Holdings's PB Ratio falls into.


;
;

Sonnet BioTherapeutics Holdings PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Sonnet BioTherapeutics Holdings's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=1.31/1.343
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Sonnet BioTherapeutics Holdings  (NAS:SONN) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Sonnet BioTherapeutics Holdings PB Ratio Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonnet BioTherapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Executives
John Markey 10 percent owner 10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter officer: Chief Technical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan director, officer: Chairman, President and CEO C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney officer: Chief Medical Officer C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg officer: Chief Medical Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini officer: Chief Scientific Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao director C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii officer: Chief Financial Officer C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc 10 percent owner 918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch 10 percent owner 515 CONGRESS AVE, STE 1400, AUSTIN TX 78701

Sonnet BioTherapeutics Holdings Headlines

From GuruFocus